Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Revenue: 2009-2025

Historic Revenue for Madrigal Pharmaceuticals (MDGL) over the last 10 years, with Sep 2025 value amounting to $287.3 million.

  • Madrigal Pharmaceuticals' Revenue rose 362.03% to $287.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $740.6 million, marking a year-over-year increase of 973.33%. This contributed to the annual value of $180.1 million for FY2024, which is 1517.03% up from last year.
  • Madrigal Pharmaceuticals' Revenue amounted to $287.3 million in Q3 2025, which was up 34.99% from $212.8 million recorded in Q2 2025.
  • Madrigal Pharmaceuticals' 5-year Revenue high stood at $287.3 million for Q3 2025, and its period low was -$4.0 million during Q4 2023.
  • Its 3-year average for Revenue is $72.8 million, with a median of $14.6 million in 2024.
  • Per our database at Business Quant, Madrigal Pharmaceuticals' Revenue plummeted by 3,485.51% in 2023 and then spiked by 3,676.08% in 2025.
  • Madrigal Pharmaceuticals' Revenue (Quarterly) stood at $52,000 in 2021, then crashed by 1,265.38% to -$606,000 in 2022, then tumbled by 555.28% to -$4.0 million in 2023, then skyrocketed by 2,701.86% to $103.3 million in 2024, then skyrocketed by 362.03% to $287.3 million in 2025.
  • Its Revenue was $287.3 million in Q3 2025, compared to $212.8 million in Q2 2025 and $137.2 million in Q1 2025.